#SmMt - Twitter Hashtag

SMMT VIEW @smmtview1993

about 1 hour ago

📸 260928 동심 @ 한양대학교 - HAON, NOWIMYOUNG 📷: _miaurluv, haoninoah #smmt #djsmmt #써밋 #dj써밋

0

26

SMMT VIEW @smmtview1993

about 1 hour ago

📸 260929 청춘화원 @ 정화예슬대학교 - HAON 📷: haoninoah, vhs_68 #smmt #djsmmt #써밋 #dj써밋

1

0

22

SMMT VIEW @smmtview1993

about 2 hours ago

🔖260929 📷: madly_medley, kcthecompany #smmt #djsmmt #써밋 #dj써밋

0

13

end

@zhngni812684531

about 4 hours ago

Semiconductors came back today. You can clearly feel capital stepping in to absorb the selling, and the sector’s rotation/inflow remains fairly strong. As for #SMMT, market expectations may still need some time to be digested and realized. In the near term, it still depends on whether follow-through capital recognition and fundamental catalysts can keep pace

end

@zhngni812684531

about 21 hours ago

$SMMT rose as much as about 16% after hours. The market is focusing on AstraZeneca’s $2 billion equity investment and its plan to incorporate ivonescimab into its own ADC clinical studies. The investment corresponds to a common-share price of $18.36, above the day’s closing price. The two sides have signed a combination-trial agreement in gastrointestinal cancers, while broader joint development is still under discussion. I think this gives ivonescimab additional capital and clinical resources.The next things to watch are whether the trials can get underway, and whether the combination data can support new indications

zhngni812684531's tweet photo. $SMMT rose as much as about 16% after hours. The market is focusing on AstraZeneca’s $2 billion equity investment and its plan to incorporate ivonescimab into its own ADC clinical studies. The investment corresponds to a common-share price of $18.36, above the day’s closing price. The two sides have signed a combination-trial agreement in gastrointestinal cancers, while broader joint development is still under discussion. I think this gives ivonescimab additional capital and clinical resources.The next things to watch are whether the trials can get underway, and whether the combination data can support new indications

0

1

2

0

142

0

19

Keydaqb

@Keyshawn_H7

about 4 hours ago

🚀 $SMMT — $2B FROM ASTRAZENECA AstraZeneca agreed to invest $2B in Summit Therapeutics through convertible preferred shares, tied to an implied $18.36/share. Now the focus shifts to ivonescimab data, combinations, and what this validation means for long-term value. #SMMT #Biotech #Cancer #Investing

0

58

SMMT VIEW @smmtview1993

about 4 hours ago

🗓 2026 October (as of 260929) #smmt #djsmmt #써밋 #dj써밋

0

23

SMMT VIEW @smmtview1993

about 4 hours ago

🗓 261024 GUMI HIPHOP FESTIVAL 📷: hiphopvibe_festa #smmt #djsmmt #써밋 #dj써밋

0

1

0

29

SMMT VIEW @smmtview1993

about 5 hours ago

⏳️260929 #smmt #djsmmt #써밋 #dj써밋

0

23

SMMT VIEW @smmtview1993

about 5 hours ago

🗓 2026 September (as of 260929) #smmt #djsmmt #써밋 #dj써밋

1

0

24

SMMT VIEW @smmtview1993

about 5 hours ago

🗓 261004 Grain Haus 📷: grainhaus.seoul #smmt #djsmmt #써밋 #dj써밋

0

27

Daniel Parker @DanParkerMacro

about 6 hours ago

$SMMT Its valuation hinges almost entirely on a single drug: ivonescimab (SMT112)—a PD-1/VEGF bispecific antibody developed by Akeso, for which Summit holds development and commercialization rights in most markets outside of China and the U.S. Target Price: $18–$22 #SMMT #NVDA

DanParkerMacro's tweet photo. $SMMT Its valuation hinges almost entirely on a single drug: ivonescimab (SMT112)—a PD-1/VEGF bispecific antibody developed by Akeso, for which Summit holds development and commercialization rights in most markets outside of China and the U.S.

Target Price: $18–$22
#SMMT
#NVDA https://t.co/hbvVLim5lo

0

44

أسهم امريكى حلال @sahmamreky

about 7 hours ago

#SMMT منطقة الدخول: $18.00 – $18.20 (بشرط التماسك فوق الدعم) الهدف الأول: $18.80 (اختراق متوسط MA20) الهدف الثاني: $19.80 (استهداف قمة الـ Pre-Market) وقف الخسارة (Stop Loss): $17.75 (كسر إغلاق 5 دقائق) تنبيه: ننتظر تأكيد الارتداد عند افتتاح السوق وزيادة الفوليوم لضمان الزخم!

sahmamreky's tweet photo. #SMMT
منطقة الدخول: $18.00 – $18.20 (بشرط التماسك فوق الدعم)
الهدف الأول: $18.80 (اختراق متوسط MA20)
الهدف الثاني: $19.80 (استهداف قمة الـ Pre-Market)
وقف الخسارة (Stop Loss): $17.75 (كسر إغلاق 5 دقائق)
تنبيه: ننتظر تأكيد الارتداد عند افتتاح السوق وزيادة الفوليوم لضمان الزخم! https://t.co/VjjG7EFmAi

0

1

0

881

Daniel Parker @DanParkerMacro

about 7 hours ago

$SMMT: The HARMONi-2 study has forced Wall Street to develop a model that predicts a bispecific antibody from China may outperform Keytruda in progression-free survival (PFS) for PD-L1-positive non-small cell lung cancer (NSCLC). #SMMT #Ivonescitumab

0

77